title: Comparative studies on the efficacy of AmBisome and Fungizone in a mouse model of disseminated aspergillosis.
abstract: OBJECTIVE
  The efficacy of intravenous injections of a liposomal formulation of amphotericin B (AmBisome) and amphotericin B deoxycholate (Fungizone) was evaluated in immunocompetent and temporarily leucopenic mouse models of disseminated aspergillosis using seven isolates of Aspergillus.
  
  
  METHODS
  Mice were infected with the organisms via tail veins. At 4 h after infection, antifungals were administered intravenously. For 30 days the number of mice surviving was recorded.
  
  
  RESULTS
  AmBisome at 1 mg/kg or higher significantly prolonged the survival time of mice infected with five out of seven isolates of Aspergillus compared with the control group. There was no difference in in vivo activity between AmBisome and Fungizone at 1 mg/kg in six isolates of Aspergillus. At the maximum tolerated dose of antifungals, however, AmBisome (10 mg/kg) showed greater efficacy than Fungizone (1 mg/kg).
  
  
  CONCLUSIONS
  These results suggest that the overall protective activity of AmBisome against disseminated aspergillosis is superior to that of Fungizone.
authors.affiliation: Sumitomo Pharmaceuticals Research Division, 1-98, Kasugadenaka 3-chome, Konohana-ku, Osaka 554-0022, Japan. ktakemot@sumitomopharm.co.jp
authors.forename: Koji
authors.initials: K
authors.lastname: Takemoto
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Ueda
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Sumita
authors.forename: Koichiro
authors.initials: K
authors.lastname: Yoshida
authors.forename: Yoshihito
authors.initials: Y
authors.lastname: Niki
mesh_terms: D000666:Amphotericin B / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D001228:Aspergillosis / Q000188:drug therapy* / Q000382:microbiology; D001230:Aspergillus / Q000187:drug effects; D007121:Immunocompetence; D007165:Immunosuppression Therapy; D007970:Leukopenia / Q000382:microbiology; D008297:Male; D020714:Maximum Tolerated Dose; D051379:Mice; D008826:Microbial Sensitivity Tests; D016019:Survival Analysis
chemical_list: D000935:Antifungal Agents; C068538:liposomal amphotericin B; D000666:Amphotericin B